193 related articles for article (PubMed ID: 18420226)
1. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.
Shimada T; Aihara K
Math Biosci; 2008; 214(1-2):134-9. PubMed ID: 18420226
[TBL] [Abstract][Full Text] [Related]
2. Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
Laitinen S; Martikainen PM; Tammela TL; Visakorpi T
Eur Urol; 2007 Sep; 52(3):725-32. PubMed ID: 17141945
[TBL] [Abstract][Full Text] [Related]
3. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression.
Yang J; Zhao TJ; Yuan CQ; Xie JH; Hao FF
J Theor Biol; 2016 Sep; 404():66-72. PubMed ID: 27259386
[TBL] [Abstract][Full Text] [Related]
4. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer.
Hirata Y; Bruchovsky N; Aihara K
J Theor Biol; 2010 May; 264(2):517-27. PubMed ID: 20176032
[TBL] [Abstract][Full Text] [Related]
5. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy.
Suzuki T; Aihara K
Math Biosci; 2013 Sep; 245(1):40-8. PubMed ID: 23648278
[TBL] [Abstract][Full Text] [Related]
7. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
8. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
10. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
11. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.
Jackson TL
Neoplasia; 2004; 6(6):697-704. PubMed ID: 15720795
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
13. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
Seruga B; Tannock IF
Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739
[No Abstract] [Full Text] [Related]
14. Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer.
Suzuki T; Bruchovsky N; Aihara K
Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5045-59. PubMed ID: 20921011
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
17. Mathematical modelling of prostate cancer growth and its application to hormone therapy.
Tanaka G; Hirata Y; Goldenberg SL; Bruchovsky N; Aihara K
Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5029-44. PubMed ID: 20921010
[TBL] [Abstract][Full Text] [Related]
18. Comparison between mathematical models of intermittent androgen suppression for prostate cancer.
Hatano T; Hirata Y; Suzuki H; Aihara K
J Theor Biol; 2015 Feb; 366():33-45. PubMed ID: 25451517
[TBL] [Abstract][Full Text] [Related]
19. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
20. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
